Omega-3 Fatty Acids and Fish Oil for Rheumatoid Arthritis

If you have rheumatoid arthritis and you have ever walked down a supplement aisle, you have been offered a hundred things that "fight inflammation." Almost none of them have been tested properly in people with your disease. Fish oil is the exception. It has been through more than twenty randomised controlled trials in rheumatoid arthritis specifically — not in mice, not in "joint health" generally, but in people with RA — and it has been pooled into several independent meta-analyses. That puts it in a very small club.

So this article is going to do something slightly unusual: it is going to tell you that a natural supplement genuinely works, and then spend just as much effort telling you exactly what it does not do. Both halves matter. Omega-3 is one of the best-supported non-drug interventions in RA. It is also, unambiguously, an adjunct — something you add on top of disease-modifying therapy, not something you swap in for it. The 2022 American College of Rheumatology guideline on integrative interventions makes that framing explicit in its opening objective: these things are for use in conjunction with disease-modifying antirheumatic drugs.

Said plainly and only once, because you do not need it repeated in every paragraph: fish oil can make your joints feel better and can let you take fewer painkillers. It will not stop your joints being eaten. Methotrexate and biologics do that. Keep taking them.

Table of Contents

  1. What Omega-3 Actually Is
  2. The Mechanism: Rewriting the Inflammation Recipe
  3. Resolvins, Protectins and Maresins: Inflammation Has an Off Switch
  4. What the Trials Actually Found
  5. The NSAID-Sparing Effect — the Most Reproducible Finding
  6. The Dose That Separates Positive Trials From Null Ones
  7. Time Course: Why Twelve Weeks Is the Honest Minimum
  8. What Omega-3 Does Not Do
  9. Food First: Fish, and How Far Diet Alone Gets You
  10. Choosing a Supplement: Form, Freshness and Oxidation
  11. The Omega-6 to Omega-3 Ratio, in Context
  12. The Omega-3 Index Blood Test
  13. Safety, Bleeding and Interactions
  14. Putting It Together
  15. Key Research Papers
  16. Connections
  17. Featured Videos

1. What Omega-3 Actually Is

"Omega-3" is not one substance. It is a family of fats defined by a chemical detail — a double bond three carbons from the tail end of the molecule. Three members matter for you:

Here is the part that trips people up. Your body can convert ALA into EPA, and EPA into DHA. It just does it terribly. In adult humans the conversion of ALA to EPA runs at a few percent at best, and the onward conversion to DHA is worse still — often well under one percent. Conversion is somewhat better in women of reproductive age, and it is throttled further by a diet high in omega-6 linoleic acid, because both fats compete for the same desaturase enzymes.

The practical consequence: flaxseed oil is not fish oil. Ground flax is a genuinely good food for other reasons, but you cannot reach an RA-relevant EPA+DHA intake through ALA. Every trial that showed benefit in rheumatoid arthritis used preformed EPA and DHA — from fish, from fish oil, from cod liver oil, or from algal oil. If you are vegetarian or vegan, algal oil is the answer, not flax: microalgae are where fish get their omega-3 in the first place, and algal oil delivers preformed DHA (and, in newer products, EPA as well).

2. The Mechanism: Rewriting the Inflammation Recipe

Think of the membrane of every cell in your body as a pantry. When an immune cell decides to mount an inflammatory response, it does not go shopping — it reaches into its own membrane and grabs whatever twenty-carbon fatty acid is stocked there. Then it feeds that fat into two enzyme systems, cyclooxygenase (COX) and lipoxygenase (LOX), and the products of those enzymes are the actual molecules of inflammation: prostaglandins, thromboxanes, leukotrienes.

On a typical Western diet, the fat sitting in that pantry is overwhelmingly arachidonic acid (AA), a twenty-carbon omega-6. Run AA through COX and you get 2-series prostaglandins — including prostaglandin E2, the molecule that sensitises pain nerves, drives fever, and helps stimulate the bone-resorbing signals that matter enormously in RA. Run AA through 5-LOX and you get 4-series leukotrienes, above all leukotriene B4, one of the most powerful neutrophil-recruiting signals your body makes. LTB4 is a large part of why an inflamed rheumatoid joint fills with immune cells.

Now change what is in the pantry. When you take EPA and DHA for long enough, they are physically incorporated into cell membrane phospholipids — and they do so partly at the expense of arachidonic acid. The pantry restocks. Two things follow:

  1. Less substrate. There is simply less AA available to be released, so less raw material for PGE2 and LTB4.
  2. Different products. EPA is itself a substrate for the same COX and LOX enzymes — but because it has one more double bond, the products come out one series different. COX turns EPA into 3-series prostaglandins (PGE3) and thromboxane A3. 5-LOX turns it into 5-series leukotrienes (LTB5). These are not inert — but they are markedly weaker. LTB5 is a far poorer neutrophil chemoattractant than LTB4, by something on the order of tenfold or more.

The useful analogy is that omega-3 does not switch the inflammation factory off. It changes the recipe the factory is following, so that the same machinery turns out a milder product. That is also why the effect is slow: you have to restock every membrane in the body, and membranes turn over on a scale of weeks to months, not hours.

There is a second, quieter mechanism worth knowing. EPA and DHA also act on gene expression — damping NF-κB signalling (the master switch for TNF-α, IL-1β and IL-6 production) and activating PPAR-γ, which pushes macrophages toward a less inflammatory phenotype. And DHA in particular alters the physical organisation of lipid rafts in the T-cell membrane, which blunts how readily T cells are activated. Philip Calder's review in Biochemical Society Transactions is the clearest single summary of these overlapping routes.

3. Resolvins, Protectins and Maresins: Inflammation Has an Off Switch

For most of the twentieth century, the assumption was that inflammation ends passively — the signals run out, and things quiet down. That turned out to be wrong, and the correction is one of the more genuinely exciting stories in modern immunology.

Charles Serhan's group at Harvard showed that resolution is an active, programmed process driven by its own dedicated family of signalling molecules, called specialised pro-resolving mediators (SPMs). And they are made from omega-3. The main families:

What SPMs do is distinct from what anti-inflammatory drugs do. An NSAID blocks the production of an inflammatory signal. An SPM tells the inflammation that has already happened to wind up and clean up: stop recruiting neutrophils, trigger apoptosis in the neutrophils already there, switch macrophages into a scavenging mode that eats the debris, and promote tissue repair. Crucially, they do this without immunosuppression — they end an inflammatory episode rather than preventing you from mounting one.

The relevance to rheumatoid arthritis is direct and, I think, under-appreciated. RA is not really a disease of too much inflammation starting. It is a disease of inflammation that never finishes — a synovial joint stuck permanently in the recruitment phase. A failure of resolution is a much better description of a rheumatoid joint than a failure of restraint. If the substrate for the resolution programme is in short supply, the programme runs weakly.

An honest caveat: the SPM story is superbly worked out in cells and animals, and the human trial evidence that supplementing omega-3 raises SPM levels enough to change RA outcomes through that specific route is still developing. Do not let anyone sell you an "SPM supplement" on the strength of certainty that does not yet exist. But as an explanation for why fish oil behaves differently from an NSAID — slower, gentler, and not obviously immunosuppressive — it is the best account we have.

4. What the Trials Actually Found

Fish oil in RA has been studied since the mid-1980s. Pooling that literature, the consistent findings are:

Two later meta-analyses put numbers around it. Lee, Bae and Song, in Archives of Medical Research (2012), pooled ten RCTs of omega-3 given at 2.7 g/day or more for at least three months. Their result is worth stating precisely, because it is more sobering than it is usually reported: NSAID consumption was the only outcome that reached statistical significance. Tender joint count, swollen joint count, morning stiffness and physical function all moved in the right direction but none of them reached significance in that pooled analysis. Gioxari and colleagues, in Nutrition (2018), systematically reviewed omega-3 intake in RA and reached a broadly similar conclusion: benefit is real, benefit is modest, and benefit is dose-dependent. Senftleber and colleagues, looking at marine oil supplements for arthritis pain in Nutrients (2017), found the pain effect small overall — but notably more consistent in rheumatoid arthritis than in osteoarthritis, which is exactly what the mechanism predicts, since RA is the immune-mediated one.

The single most interesting modern trial is Proudman and colleagues' study in Annals of the Rheumatic Diseases (2015), because of how it was designed. DMARD-naive patients with RA of under twelve months' duration were all put on a treat-to-target triple-DMARD algorithm — methotrexate, sulfasalazine and hydroxychloroquine, real modern therapy — and then randomised to fish oil at 5.5 g/day of EPA+DHA or a masking low dose of 0.4 g/day. The fish-oil group did better on the algorithm: failure of triple DMARD therapy was substantially less likely, and the rate of first ACR remission was about twice as high. Methotrexate dose, DAS28 and disability scores did not differ between the groups, and neither did adverse events. That is the design that answers the question patients actually ask. Not "does fish oil work instead of drugs" but "does adding fish oil to proper treatment make proper treatment work better?" In that trial, it did.

Two smaller trials are worth knowing because they point at combinations rather than fish oil alone. Adam and colleagues (Rheumatology International, 2003) tested fish oil against a background diet deliberately low in arachidonic acid, and found the combination outperformed either alone — you get more from restocking the pantry if you also stop restocking it with AA. Berbert and colleagues (Nutrition, 2005) found fish oil plus olive oil gave greater improvement than fish oil alone. Neither trial was large, but both suggest fish oil is a diet intervention as much as a supplement one, which is why the anti-inflammatory diet page is a companion to this one rather than a competitor.

Finally, there is prevention, and it works at a very different dose. Di Giuseppe and colleagues followed more than 32,000 Swedish women and found that a dietary intake of long-chain omega-3 above just 0.21 g/day was associated with a 35% lower risk of developing RA, rising to about 52% lower in the women whose intake was consistently above that level across two dietary surveys a decade apart. Their separate estimate for eating fish at least once a week pointed the same way but did not reach statistical significance, so treat the fish-servings version of this finding as suggestive rather than established. Note how small the preventive intake is: a fifth of a gram a day is roughly one oily-fish meal a week, and nowhere near the multi-gram doses used to treat established disease. And Gan and colleagues found that in people who were already anti-CCP antibody positive but did not yet have arthritis, higher omega-3 levels in red blood cell membranes tracked with lower odds of having crossed into inflammatory arthritis. These are observational, so they cannot prove causation. But they are pointing the same direction as the trials.

5. The NSAID-Sparing Effect — the Most Reproducible Finding

If you take one thing from this page, take this one.

Across the RA literature, the effect that reproduces most reliably is not pain reduction and not joint counts. It is that people taking adequate doses of fish oil need fewer NSAIDs. Galarraga and colleagues built an entire trial around exactly this question, published in Rheumatology (2008). Patients on cod liver oil were compared with placebo, and the outcome measured was whether they could cut their daily NSAID dose by 30% or more without their disease getting worse. Roughly four in ten of the cod-liver-oil group managed it, against roughly one in ten on placebo — and disease activity did not deteriorate in those who cut back.

Kremer's 1995 trial in Arthritis & Rheumatism came at it from the other end: patients on high-dose fish oil stopped their NSAIDs, and the group's clinical status was assessed afterwards. Kremer's later summary in the American Journal of Clinical Nutrition (2000) treats the NSAID-sparing effect as the clinically meaningful outcome of the whole literature.

Why does this matter so much? Because NSAIDs are not benign, and people with RA take them for decades. Long-term NSAID use carries real risks of gastrointestinal bleeding and ulceration, kidney injury, hypertension, and elevated cardiovascular risk — and RA already carries elevated cardiovascular risk. A supplement that lets you take meaningfully less ibuprofen, naproxen or diclofenac over twenty years is doing something genuinely valuable for your stomach, your kidneys and your heart, even if it never moves a single DAS28 point.

That reframing also explains a common disappointment. People start fish oil expecting their pain score to drop dramatically. It usually does not. What often happens instead is subtler: the ibuprofen you used to need every day, you now need three days a week. That is the effect working. It is just not the effect people were watching for.

6. The Dose That Separates Positive Trials From Null Ones

This section is the single most common reason people conclude "fish oil didn't work for me." They were not taking enough. Usually not remotely enough.

The threshold that emerges from the trial literature is around 2.7 grams per day of combined EPA plus DHA, sustained for at least three months. That specific figure comes from Lee, Bae and Song, who built it into their meta-analysis as an entry criterion — they pooled only trials dosing at or above 2.7 g/day for three months or longer, and concluded that at that dose omega-3 reduces NSAID consumption in RA. Trials at or above that level tend to be positive. Trials below it tend to be null. It is close to a dividing line. Note that Proudman's trial went considerably higher still, at 5.5 g/day.

Now compare that with what is in the bottle. A standard, cheap, non-concentrated "1000 mg fish oil" capsule contains one gram of oil, of which typically about 300 mg is actual EPA+DHA — conventionally 180 mg EPA and 120 mg DHA. So:

Product type Typical EPA+DHA per capsule Capsules needed for ~2.7 g/day
Standard "1000 mg fish oil" ~300 mg About 9
Concentrated fish oil ~500–600 mg About 5
High-concentrate / triple strength ~800–900 mg About 3–4
Liquid fish oil Varies widely — often ~1000–1500 mg per 5 mL About 2–3 teaspoons

Someone taking "two fish oil capsules a day" as directed on the label is taking roughly 600 mg of EPA+DHA. That is around a fifth of the studied dose. Concluding fish oil does not work on that basis is like concluding methotrexate does not work after taking 2.5 mg once.

How to read a label properly. Ignore the number on the front of the bottle — it is the weight of the oil, not the omega-3. Turn it around, find the Supplement Facts panel, and locate the two lines that say EPA and DHA. Add them. Multiply by the number of capsules per serving. That number, and only that number, is what you compare against 2.7 g.

This dose gap also explains an important negative result. The VITAL trial tested a 1 gram per day fish oil capsule — which supplied about 840 mg of EPA+DHA — for prevention of incident autoimmune disease in the general population, and reported in the BMJ (2022) that omega-3 did not clearly reduce incident autoimmune disease in the primary analysis, while vitamin D did. Roughly 0.8 g of EPA+DHA is well under a third of the RA treatment threshold. VITAL is a fair test of low-dose prevention in healthy people. It is not a test of therapeutic-dose fish oil in established rheumatoid arthritis, and it should not be quoted as though it were.

Two practical notes on the higher doses. First, split them — three or four capsules with each of two or three meals is far easier on the stomach than nine at once, and taking them with food containing fat genuinely improves absorption. Second, if swallowing that many capsules is unrealistic, liquid fish oil in a high-concentrate form gets you there in two or three teaspoons, and the good ones are lemon-flavoured for a reason.

7. Time Course: Why Twelve Weeks Is the Honest Minimum

Fish oil is not a painkiller and it does not behave like one. If you want to know whether it is working, you have to give it a proper trial — and "proper" means at least twelve weeks at full dose, with sixteen to twenty-four weeks being a fairer test.

The reason is mechanical, and it follows directly from the mechanism. The effect depends on EPA and DHA physically replacing arachidonic acid in cell membranes. Plasma levels rise within days. Membrane incorporation in white blood cells takes weeks. Red blood cells, which are the standard tissue for measurement, live about 120 days — so the red cell pool does not fully re-equilibrate for roughly three to four months. The clinical effect tracks the membrane change, not the blood level.

Most RA trials that showed benefit ran for twelve weeks or longer, and several found that improvement was still deepening at the end of the study period. Very short trials of a few weeks are, in retrospect, a good way to generate a false negative.

So set expectations honestly:

Keep a simple record from the start — how many minutes of morning stiffness, and how many NSAID tablets in a typical week. Without a baseline written down, six months later you will genuinely not be able to tell.

8. What Omega-3 Does Not Do

Here is the boundary, stated as clearly as I know how.

Omega-3 has not been shown to reliably slow radiographic joint erosion. The trials measure symptoms — pain, stiffness, tender joints, NSAID use — and it improves those. They do not show that fish oil protects the cartilage and bone of the joint from being destroyed over years. That structural damage is what turns rheumatoid arthritis from a painful condition into a disabling one, and it is precisely what disease-modifying therapy is for.

Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, the TNF inhibitors, abatacept, rituximab, tocilizumab, the JAK inhibitors — these are the drugs with radiographic evidence behind them. They are the reason the wheelchair-and-deformity picture of RA that dominated textbooks fifty years ago is now uncommon in people treated early. No fish oil trial has ever demonstrated anything comparable.

This is not a hedge. It is the actual finding, and it defines the role. Omega-3 sits alongside your DMARD, improving how you feel and reducing what else you have to take. It does not substitute for it. Stopping methotrexate because you started fish oil is a straightforwardly bad trade: you would be exchanging a small, real symptomatic benefit for a large, real risk of permanent joint destruction. The window in which erosion can be prevented does not reopen.

A few smaller "does not do" items, for completeness:

9. Food First: Fish, and How Far Diet Alone Gets You

Food is the better delivery vehicle where it can do the job, because oily fish brings vitamin D, selenium, iodine, B12 and high-quality protein along with the omega-3 — and because a fillet cannot go rancid in a cupboard for eighteen months.

Approximate EPA+DHA content per 100 g cooked portion (values vary with season, wild versus farmed, and species):

Fish Approximate EPA+DHA per 100 g
Salmon (Atlantic) Roughly 1.5–2 g
Herring Roughly 1.5–2 g
Mackerel (Atlantic) Roughly 1–2 g
Sardines (canned in oil, drained) Roughly 1–1.5 g
Trout (rainbow) Roughly 0.8–1 g
Tuna, albacore Roughly 0.7–1 g
Tuna, canned light Roughly 0.2–0.3 g
Cod and other white fish Roughly 0.2 g — lean fish, low omega-3

Do the arithmetic and the limitation appears immediately. To hit 2.7 g/day from salmon you would need something like a 150–180 g portion every single day. That is not a realistic diet for most people, and at that frequency mercury and cost start to matter. Oily fish two or three times a week is an excellent foundation and a genuinely good idea — but it will not by itself reach the dose used in the positive RA trials. Most people who want the trial-level effect will need fish plus a supplement.

Two food notes specific to RA. Small oily fish are the sweet spot: sardines, herring, anchovies and mackerel are high in omega-3 and low on the food chain, so they accumulate far less methylmercury than large predators. Canned sardines with the soft bones are also a serious calcium source, which matters when you are on steroids. And cod liver oil is a food and a supplement at once — it was the intervention in the Galarraga trial — but it carries preformed vitamin A and vitamin D, so the dose that gets you enough EPA+DHA can also get you more retinol than is wise long term. Check the vitamin A figure on the label before treating it as a high-dose omega-3 source.

10. Choosing a Supplement: Form, Freshness and Oxidation

The supplement market is uneven, and two variables actually matter.

Triglyceride versus ethyl ester

Fish oil as it comes out of a fish is a natural triglyceride (TG) — three fatty acids attached to a glycerol backbone. To concentrate the EPA and DHA, manufacturers strip the fatty acids off and re-attach them to ethanol, producing an ethyl ester (EE). Some then re-attach them to glycerol again, giving a re-esterified triglyceride (rTG).

Dyerberg and colleagues compared these formulations head to head in Prostaglandins, Leukotrienes and Essential Fatty Acids (2010) and found the triglyceride forms were better absorbed than the ethyl ester form, with re-esterified triglyceride the best of the group. So the ordering is roughly rTG ≥ natural TG > EE.

Before you throw out your ethyl ester bottle: the difference is meaningful but not enormous, ethyl esters are what several major cardiovascular trials used, and taking them with a fat-containing meal narrows the gap considerably, because dietary fat triggers the pancreatic lipase activity that ethyl esters depend on. If your product is EE and you take it with breakfast, you are fine. If you are buying new and the price difference is small, rTG is the better buy. Labels that say only "fish oil concentrate" with no form stated are usually ethyl ester.

Oxidation — the problem nobody mentions

This deserves more attention than it gets. EPA and DHA have five and six double bonds respectively, and every double bond is a site where oxygen can attack. That makes them among the most oxidation-prone molecules in the food supply. Oxidised fish oil is not merely inactive — the peroxides and aldehydes formed are themselves pro-inflammatory, which is the exact opposite of what you bought it for.

Albert and colleagues analysed fish oil supplements sold in New Zealand and published the results in Scientific Reports (2015). Most exceeded recommended limits for oxidation markers, and only a small minority actually contained the EPA and DHA their labels claimed. There is no reason to think that market was uniquely bad.

Practical defences:

Krill and algal oil

Krill oil delivers omega-3 bound to phospholipids rather than triglycerides, which may absorb somewhat more efficiently per gram, and it contains astaxanthin as a natural antioxidant. Two catches. The first is concentration: krill capsules are usually low in EPA+DHA, so reaching 2.7 g/day is expensive and involves a lot of capsules. The second is allergy — krill are crustaceans, so krill oil is a shellfish product and must be avoided entirely by anyone with a shellfish allergy. Algal oil is the right choice for vegetarians and vegans, and for anyone with a fish allergy — it is the original source of marine omega-3, it is free of the ocean-contaminant question entirely, and modern EPA+DHA algal products can reach therapeutic doses.

11. The Omega-6 to Omega-3 Ratio, in Context

You will read a great deal online about the omega-6 to omega-3 ratio. The commonly quoted figures are that ancestral human diets ran somewhere near 1:1 to 4:1, while modern Western diets run somewhere around 10:1 to 20:1, driven by industrial seed oils and by grain-fed animal products. Treat those numbers as reasonable estimates rather than precise measurements — they are reconstructions, not measurements of anyone's actual ancestors.

The underlying biology is real, though, and it is the same competition described in the mechanism section. Omega-6 linoleic acid and omega-3 ALA compete for the same desaturase and elongase enzymes. Flood the system with linoleic acid and you push the pathway toward arachidonic acid, and you further suppress the already-poor conversion of ALA. And arachidonic acid arriving directly in the diet — from meat, egg yolk and organ meats — bypasses the conversion question entirely.

But here is the correction that matters, and where the internet usually overshoots: the ratio is less important than the absolute amount of EPA and DHA you get. You cannot fix a low omega-3 status by cutting omega-6 alone, because that just gives you a better ratio of two small numbers. Raising EPA+DHA improves the ratio and does the pharmacology at the same time. Cutting omega-6 is a useful supporting move, not the main one.

That said, Adam's trial is a direct argument that the supporting move is worth making — fish oil worked better against a background diet low in arachidonic acid than against a normal one. So the sensible practical position is: raise EPA and DHA deliberately; lower industrial seed oils and fried food opportunistically. Cook with olive oil, which also brings oleocanthal, a phenolic compound with genuine COX-inhibiting activity of its own — and which was the co-intervention in the Berbert trial. Cutting out whole food groups is unnecessary and, in a disease where undernutrition and muscle loss are real problems, potentially harmful.

12. The Omega-3 Index Blood Test

You do not have to guess whether your dose is working. There is a test.

The Omega-3 Index, developed by William Harris and Clemens von Schacky and described in Preventive Medicine (2004), measures EPA plus DHA as a percentage of the total fatty acids in your red blood cell membranes. That membrane framing is what makes it the right test: it measures the thing the mechanism actually depends on, rather than what you happened to eat yesterday. A plasma omega-3 level bounces around with your last meal. The red cell index does not — red cells live about 120 days, so the index is a rolling average of roughly the previous three to four months.

The categories Harris and von Schacky proposed, originally as cardiovascular risk bands:

Omega-3 Index Category
Below 4% Undesirable / high risk — typical of much of the United States
4–8% Intermediate
8% or above Desirable — typical of populations with high oily-fish intake, such as Japan

An important honesty note: the 8% target was derived from cardiovascular outcomes, not from rheumatoid arthritis outcomes. There is no validated Omega-3 Index target for RA symptom control. So use it for what it is genuinely good at — confirming that the dose you are taking is actually being absorbed and incorporated — rather than treating 8% as a therapeutic endpoint for your joints.

How to use it sensibly: test at baseline before starting, start your dose, then retest after three to four months (not sooner — the red cell pool has not turned over). If your index has barely moved despite good adherence, something is wrong with the product, the form, or the absorption, and that is worth knowing before you write off the whole intervention. It is available as a mail-in dried-blood-spot kit in many countries and is usually paid for out of pocket. Do not order it monthly; it cannot change that fast. See our lab tests section for the broader panel worth tracking in RA.

13. Safety, Bleeding and Interactions

Fish oil is well tolerated at the doses discussed here, and the main worry people have about it turns out to be somewhat overstated. But there are real cautions.

An honest word about the size of the dose

The dose this page describes is a therapeutic one, and it sits above some general-population advice, which you deserve to know before you start. The US Food and Drug Administration has long advised consumers not to exceed about 3 g/day of combined EPA+DHA from all sources, with no more than about 2 g/day of that coming from a supplement. The European Food Safety Authority, reviewing the same question, concluded that supplemental intakes up to 5 g/day of EPA+DHA do not raise safety concerns for adults. The RA trial doses sit above the FDA's supplement figure, and Proudman's 5.5 g/day sits above the EFSA ceiling as well — those trials were run under medical supervision with monitoring, which an unsupervised bottle from a shop is not.

The practical reading: 2.7–3 g/day is a supported and widely used dose in this disease, but it is not a casual over-the-counter amount, and it is a dose to take with your rheumatologist's knowledge rather than instead of telling them. If you have a bleeding disorder, a history of atrial fibrillation, or you are on an anticoagulant, that conversation should happen before you start rather than afterwards.

Bleeding

EPA and DHA reduce platelet aggregation — that is genuine pharmacology, and it follows from thromboxane A3 being a weaker platelet activator than thromboxane A2. The historical worry came from observations of low clotting activity in Greenland Inuit populations with very high fish intake.

What the clinical evidence shows is more reassuring. Wachira, Larson and Harris reviewed this in the British Journal of Nutrition (2014) and concluded that while omega-3 measurably affects haemostasis, it does not translate into an increased risk of clinically significant bleeding — including in patients on antiplatelet drugs and in those undergoing surgery. On the strength of that evidence, the old blanket advice to stop fish oil before every procedure has increasingly been questioned — but it has not been withdrawn everywhere, and the decision belongs to the team doing your procedure, not to a web page.

Still, be sensible and be transparent:

Atrial fibrillation

This one is newer and deserves to be stated. Large cardiovascular trials of high-dose omega-3 — REDUCE-IT with 4 g/day of icosapent ethyl, and STRENGTH with a high-dose EPA/DHA preparation — both reported a higher incidence of atrial fibrillation in the omega-3 arms than in the control arms. The absolute increase was small, and these were doses at or above the RA range in cardiac patients. But if you have a history of AF or palpitations, this is worth raising with your doctor before going to 3 g/day and above.

Everything else

Tell your rheumatologist you are taking it, at what dose, and in what form. Not as a formality — as data. If your NSAID requirement drops, that is a clinically useful fact about you, and it belongs in your notes.

14. Putting It Together

A reasonable, evidence-shaped approach:

  1. Stay on your DMARD. This is the foundation and nothing on this page changes it. See DMARDs and biologics.
  2. Write down a baseline. Minutes of morning stiffness on a typical day, and NSAID tablets per week. Thirty seconds now, invaluable in six months.
  3. Eat oily fish two to three times a week, favouring small species — sardines, herring, mackerel, anchovies. This is the foundation, not the whole dose.
  4. Add a supplement and read the label properly. Target roughly 2.7–3 g/day of combined EPA+DHA, which is the trial-level dose. Add the EPA and DHA lines on the Supplement Facts panel; ignore the front of the bottle.
  5. Choose rTG or natural triglyceride if you can, take it with a fatty meal, split the dose, and buy a two-to-three-month quantity from a third-party-tested brand. Refrigerate it.
  6. Give it twelve weeks minimum, ideally sixteen to twenty-four, before judging.
  7. Consider an Omega-3 Index at baseline and again at three to four months, if you want objective confirmation that the dose is landing.
  8. Watch the right outcome. Morning stiffness duration and NSAID consumption — not a dramatic drop in pain score.
  9. Tell your rheumatologist, and flag it specifically if you are on an anticoagulant, have a history of atrial fibrillation, or have surgery coming up.
  10. Lower industrial seed oils opportunistically and cook with olive oil. Supporting move, not the main one.

And a closing thought about proportion. Omega-3 will not transform your rheumatoid arthritis. What it will plausibly do, at an adequate dose over an adequate time, is shave meaningful minutes off your morning stiffness and let you reach for the ibuprofen bottle noticeably less often over the coming decades. In a chronic disease measured in decades, that is not a small thing — it just is not a dramatic one. Fish oil has earned the modest, real place it occupies. The mistake is not taking it. The mistakes are taking too little, giving up too early, and — the only one that truly costs you — taking it instead of the drugs that protect your joints.

15. Key Research Papers

Every citation below was checked against the Crossref registry before publication. Journal names and titles are plain text; the linked portion is the volume, issue and page reference, which resolves to the paper itself.

Clinical trials and meta-analyses in rheumatoid arthritis

  1. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007;129(1):210–223. — Pooled 17 randomised trials in RA, inflammatory bowel disease and dysmenorrhoea; significant reductions in patient-reported pain, morning stiffness, painful/tender joint count and NSAID consumption at 3–4 months.
  2. Lee YH, Bae SC, Song GG. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. Archives of Medical Research. 2012;43(5):356–362. — The source of the ≥2.7 g/day threshold; pooled 10 RCTs, in which NSAID consumption was the only outcome reaching statistical significance.
  3. Proudman SM, James MJ, Spargo LD, Metcalf RG, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Annals of the Rheumatic Diseases. 2015;74(1):89–95. — Fish oil added to treat-to-target triple DMARD therapy.
  4. Galarraga B, Ho M, Youssef HM, Hill A, et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology. 2008;47(5):665–669. — The dedicated NSAID-sparing trial.
  5. Kremer JM, Lawrence DA, Petrillo GF, Litts LL, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs: clinical and immune correlates. Arthritis & Rheumatism. 1995;38(8):1107–1114.
  6. Kremer JM. n-3 fatty acid supplements in rheumatoid arthritis. American Journal of Clinical Nutrition. 2000;71(1):349S–351S.
  7. Gioxari A, Kaliora AC, Marantidou F, Panagiotakos DP. Intake of ω-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a systematic review and meta-analysis. Nutrition. 2018;45:114–124.
  8. Senftleber NK, Nielsen SM, Andersen JR, Bliddal H, et al. Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. Nutrients. 2017;9(1):42.
  9. Adam O, Beringer C, Kless T, Lemmen C, et al. Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatology International. 2003;23(1):27–36.
  10. Berbert AA, Kondo CRM, Almendra CL, Matsuo T, et al. Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. Nutrition. 2005;21(2):131–136.
  11. England BR, Smith BJ, Baker NA, Barton JL, et al. 2022 American College of Rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Care & Research. 2023;75(8):1603–1615. — Frames all integrative interventions as adjuncts to DMARDs; exercise received the only strong recommendation.

Mechanism: eicosanoids and pro-resolving mediators

  1. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions. 2017;45(5):1105–1115. — The clearest single overview of membrane incorporation, eicosanoid shifting and gene-level effects.
  2. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92–101.
  3. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. Journal of Clinical Investigation. 2018;128(7):2657–2669. — Resolvins, protectins and maresins.
  4. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. Journal of Lipid Research. 2009;50:S29–S34. — Background on the COX enzymes that both arachidonic acid and EPA compete for.

Formulation, measurement and dietary status

  1. Dyerberg J, Madsen P, Møller JM, Aardestrup I, et al. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2010;83(3):137–141. — Triglyceride versus ethyl ester absorption.
  2. Albert BB, Derraik JGB, Cameron-Smith D, Hofman PL, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Scientific Reports. 2015;5:7928. — The oxidation and label-accuracy problem.
  3. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine. 2004;39(1):212–220. — The original description of the red-cell index and its risk bands.

Risk, prevention and safety

  1. Di Giuseppe D, Wallin A, Bottai M, Askling J, et al. Long-term intake of dietary long-chain n-3 polyunsaturated fatty acids and risk of rheumatoid arthritis: a prospective cohort study of women. Annals of the Rheumatic Diseases. 2014;73(11):1949–1953.
  2. Gan RW, Bemis EA, Demoruelle MK, Striebich CC, et al. The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population. Rheumatology. 2017;56(12):2229–2236.
  3. Hahn J, Cook NR, Alexander EK, Friedman S, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452. — A low-dose (1 g/day) prevention trial; useful as a dose-threshold illustration, not as a test of therapeutic dosing in established RA.
  4. Manson JE, Cook NR, Lee IM, Christen W, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine. 2019;380(1):23–32. — The parent VITAL trial.
  5. Wachira JK, Larson MK, Harris WS. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. British Journal of Nutrition. 2014;111(9):1652–1662.
  6. Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11–22. — REDUCE-IT; source of the high-dose atrial fibrillation signal.
  7. Nicholls SJ, Lincoff AM, Garcia M, Bash D, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk. JAMA. 2020;324(22):2268. — STRENGTH; the second high-dose trial reporting more atrial fibrillation.
  8. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12).

Live PubMed Searches

These links run a live search on PubMed, so they stay current as new studies appear.

  1. Omega-3 in RA — randomised trials
  2. Fish oil in RA — meta-analyses
  3. NSAID-sparing effect of fish oil
  4. EPA/DHA dose–response in inflammation
  5. Pro-resolving mediators in arthritis
  6. Resolvins, protectins and maresins
  7. Arachidonic acid and leukotriene B4 in RA
  8. Omega-3 Index (red cell EPA+DHA)
  9. Fish oil oxidation and supplement quality
  10. Triglyceride vs ethyl ester bioavailability
  11. Omega-3, bleeding risk and anticoagulants
  12. Omega-3 and atrial fibrillation risk
  13. Algal oil for vegetarian omega-3
  14. Omega-6 to omega-3 ratio and inflammation
  15. ALA conversion to EPA and DHA in humans
  16. Diet and RA disease activity

16. Connections

↑ Back to Table of Contents